NEWROFEED
Personalized medical device for the diagnosis and treatment of ADHD based on EEG biomarkers and Neurofeedback Training
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0NEWROFEED project word cloud
Explore the words cloud of the NEWROFEED project. It provides you a very rough idea of what is the project "NEWROFEED" about.
Project "NEWROFEED" data sheet
The following table provides information about the project.
| Coordinator |
MENSIA TECHNOLOGIES
Organization address contact info |
| Coordinator Country | France [FR] |
| Project website | http://www.newrofeed.com/ |
| Total cost | 3˙600˙632 € |
| EC max contribution | 3˙600˙632 € (100%) |
| Programme |
1. H2020-EU.2.1.3. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials) 2. H2020-EU.3.1.3. (Treating and managing disease) |
| Code Call | H2020-SMEINST-2-2015 |
| Funding Scheme | SME-2 |
| Starting year | 2015 |
| Duration (year-month-day) | from 2015-10-01 to 2018-03-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | MENSIA TECHNOLOGIES | FR (CHANTEPIE) | coordinator | 3˙600˙632.00 |
Map
Project objective
NEWROFEED aims at setting a new standard of care for children suffering from Attention Deficit Hyperactivity Disorder (ADHD). ADHD@Home is the diagnosis and treatment medical device, developed by Mensia in project NEWROFEED, to achieve this goal. In order to optimise success rates, ADHD@Home is based on an EEG biomarker-based personalised medicine approach to treat ADHD children with state-of-the-art personalized Neurofeedback Training. This patient-centered solution is delivered at home, with supervision by ADHD specialists. As an efficacious alternative to treatment by psychoactive medication, the expected clinical outcomes include normalized social behaviour and improved school performance. ADHD@Home delivers physiological lasting normalization of brain activity, using the child’s endogenous neuronal plasticity, to resolve his or her attention and hyperactivity problems. Its unique technology and design enable it to achieve two critical clinical objectives: 1. To identify the root cause of the ADHD for a given child by quantifying, in real-time, deviations in EEG oscillation biomarkers allowing the clinician to select and adjust the Neurofeedback protocols. 2. To deliver the personalized Neurofeedback protocols on an affordable and user-friendly device, enabling optimal training at home under remote medical supervision. This clinical breakthrough is made possible by Mensia’s cloud-based real time quantitative EEG analysis technology. ADHD@Home will be validated for efficacy in the NEWROFEED Clinical Trial. This will pave the way for a successful commercial launch in 2018 to deliver on our promise of efficacious physiological treatment for millions of ADHD children. Thanks to NEWROFEED, Mensia will become a world leader in the field of EEG-based personalised treatment of Central Nervous System disorders; capitalizing on the clinical success of its ADHD@Home device that will generate 65M€ in cumulative revenues by 2022.
Deliverables
| Project website | Websites, patent fillings, videos etc. | 2019-05-30 13:57:45 |
Take a look to the deliverables list in detail: detailed list of NEWROFEED deliverables.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NEWROFEED" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "NEWROFEED" are provided by the European Opendata Portal: CORDIS opendata.